

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/127429 A1

(51) International Patent Classification:

A61K 31/131 (2006.01) C07D 221/04 (2006.01)
A61K 31/50 (2006.01) C07D 237/00 (2006.01)
A61K 31/5025 (2006.01) C07D 237/26 (2006.01)

(21) International Application Number:

PCT/US2020/066003

(22) International Filing Date:

18 December 2020 (18.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/951,812 20 December 2019 (20.12.2019) US
62/975,645 12 February 2020 (12.02.2020) US
63/044,802 26 June 2020 (26.06.2020) US

(71) Applicant: **MIRATI THERAPEUTICS, INC.** [US/US];
9393 Towne Center Dr., Suite 200, San Diego, CA 92121
(US).

(72) Inventors: **MARX, Matthew, Arnold**; c/o Mirati Therapeutics, Inc., 9393 Towne Dr., Suite 200, San Diego, CA 92121 (US). **KETCHAM, John, Michael**; c/o Mirati Therapeutics, Inc., 9393 Towne Center Dr., Suite 200, San Diego, CA 92121 (US). **SMITH, Christopher, Ronald**; c/o Mirati Therapeutics, Inc., 9393 Towne Center Dr., Suite 200, San Diego, CA 92121 (US). **LAWSON, John, David**; c/o Mirati Therapeutics, Inc., 9393 Towne Center Dr., Suite 200, San Diego, CA 92121 (US). **BURNS, Aaron, Craig**; c/o Mirati Therapeutics, Inc., 9393 Towne Center Dr., Suite 200, San Diego, CA 92121 (US). **WANG, Xiaolun**; c/o Mirati Therapeutics, Inc., 9393 Towne Center Dr., Suite 200, San Diego, CA 92121 (US). **KULYK, Svitlana**; c/o Mirati Therapeutics, Inc., 9393 Towne Center Dr., Suite 200, San Diego, CA 92121 (US). **IVETAC, Anthony**; c/o Mirati Therapeutics, Inc., 9393 Towne Center Dr., Suite 200, San Diego, CA 92121 (US).

(74) Agent: **POLYAKOV, Mark, V.** et al.; Wood, Phillips, Katz, Clark & Mortimer, 500 West Madison Street, Suite 1130, Chicago, IL 60661 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: SOS1 INHIBITORS

(57) Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.



WO 2021/127429 A1